Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic avenue for managing metabolic conditions. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon output. GLP-1 peptides demonstrate promising therapeutic results in treating type 2 d